John shares a fascinating look into the drug discovery process, highlighting the remarkable potency of Obacibatrib. With a staggering 27% reduction in LDL at just 1 mg and a 97% inhibition of CETP, this compound shows promise beyond traditional heart disease treatments. As they delve into the genetic and epidemiological data, the conversation reveals a broader understanding of the drug's potential impact.
